comprehensive -WSS

comprehensive

author：entertainment 2025-08-25 16:33:35 - browse：254

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Vertex cell therapy lets patients with type 1 diabetes stop insulin

explore

hotspot

WSS

How Robert F. Kennedy Jr. distorted vaccine science

Hospitals are dialing back on venture capital investing

Idaho college killings prosecutors challenge defense's grand jury claims

Canadians with cystic fibrosis outlive Americans by a decade

Senators push IRS to launch nonprofit hospital probe

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

explore

comprehensive

hotspot

Activists slam private health insurers over coverage restrictions

Treatments for cramps don't cut it. Why aren't there better options?

At least 13 dead in Texas as scorching temps continue

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Virginia high school admissions case could be legal follow

Dozens dead from Maui wildfires: What we know about the victims

Jerome Adams on the need for new antivirals for Covid

Treatments for cramps don't cut it. Why aren't there better options?

At least 13 dead in Texas as scorching temps continue

Idaho college killings prosecutors challenge defense's grand jury claims

Wikipedia

Novo Nordisk touts Wegovy study, but still struggling with supply

Patients, digital health players weigh in on FTC's data privacy plan

What affirmative action's end means to a medical student

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

A letter from the executive editor: The 2023 STATUS List

Security flaws in third

explore

entertainment

hotspot

hotspot